Live Analyst Rating Changes 26562 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Daina Graybosch
LP

Daina Graybosch

Leerink Partners
Wall Street Analyst
★★★★☆
#323
on 13Foresight · ranked by our own returns
58%
Success Rate
+28.2%
Average Return
15 of 26 calls profitable · +79.8% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 58% of Daina Graybosch's ratings turned a profit when each position was held for 1 year — averaging +28.2% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

18 Buy 7 Hold 3 Sell
Daina's Stock Coverage 26 ratings · 2026-08-21
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
IPHA
Innate Pharma
 Aug 11, 2026 BUY Strong Buy
+234.5% avg upside
10 analysts
$4.00
91.48% Upside
 +1.4% ·
REPL
Replimune Group
 Aug 03, 2026 BUY Strong Buy
+63.4% avg upside
14 analysts
$17.00
20.91% Upside
 +18.0% ·
GILD
Gilead Sciences
 Jul 20, 2026 HOLD Strong Buy
-17.3% avg upside
66 analysts
$127.00
11.46% Downside
 +7.7% ·
CGEN
Compugen
 May 21, 2026 BUY Strong Buy
+104.6% avg upside
8 analysts
$5.00
88.65% Upside
 -7.7% ·
RCUS
Arcus Biosciences
 Apr 20, 2026 BUY Strong Buy
+20.5% avg upside
20 analysts
$47.00
59.31% Upside
 +33.6% ·
BNTX
BioNTech SE
 Feb 02, 2026 HOLD Strong Buy
+21.7% avg upside
26 analysts
$113.00
1.82% Upside
 -14.8% ·
MRK
Merck & Company
 Dec 15, 2025 BUY Strong Buy
-10.4% avg upside
43 analysts
$114.00
23.50% Downside
 +54.0% ·
IPSC
Century Therapeutics
 Nov 17, 2025 HOLD Strong Buy
+163.6% avg upside
11 analysts
$2.00
1.04% Downside
 +300.0% ·
SMMT
Summit Therapeutics
 Oct 22, 2025 SELL Buy
+130.0% avg upside
28 analysts
 — +30.3% ·
NBP
NovaBridge Biosciences
 Oct 06, 2025 BUY Strong Buy
+1007.1% avg upside
14 analysts
$9.00
371.27% Upside
 -54.9% ·
FATE
Fate Therapeutics
 Sep 04, 2025 BUY Buy
+393.2% avg upside
31 analysts
$7.00
185.65% Upside
 +164.9% ·
BOLT
Bolt Biotherapeutics
 Sep 04, 2025 HOLD Buy
+711.7% avg upside
7 analysts
$6.00
87.47% Upside
 -30.8% ·
HOWL
Werewolf Therapeutics
 Sep 04, 2025 BUY Strong Buy
+1501.1% avg upside
8 analysts
$10.00
2219.20% Upside
 -70.4% ·
XLO
Xilio Therapeutics
 Aug 15, 2025 BUY Strong Buy
+86.3% avg upside
7 analysts
$28.00
203.34% Upside
 -7.6% ·
ADAG
Adagene
 Aug 13, 2025 BUY Strong Buy
+82.0% avg upside
8 analysts
$7.00
71.23% Upside
 +125.4% ·
NKTX
Nkarta
 Aug 13, 2025 BUY Strong Buy
+647.8% avg upside
16 analysts
$8.00
223.87% Upside
 +4.1% ·
AFMDQ
Affimed
 May 14, 2025 HOLD Buy
+14226263.6% avg upside
16 analysts
$0.39
389899.94% Upside
 · ·
TIP
iShares TIPS Bond ETF
 Nov 08, 2024 BUY Strong Buy
1 analyst
 — +5.4% ·
MOLN
Molecular Partners
 Aug 28, 2024 HOLD Strong Buy
+135.3% avg upside
7 analysts
$6.00
41.84% Upside
 -43.1% ·
ASH
Ashland
 Dec 11, 2023 BUY Strong Buy
+7.8% avg upside
16 analysts
 — -7.8% ·
NKTR
Nektar Therapeutics
 Sep 15, 2023 HOLD Strong Buy
+0.6% avg upside
26 analysts
$1.50
97.92% Downside
 +84.5% ·
LINK
Interlink Electronics
 Jun 05, 2023 BUY Strong Buy
+98.3% avg upside
16 analysts
 — -28.8% ·
SPRY
ARS Pharmaceuticals
 Apr 01, 2022 HOLD Strong Buy
+283.0% avg upside
12 analysts
$1.80
67.28% Downside
 +102.8% ·
CH:MOLN
Molecular Partners AG
 Apr 06, 2021 BUY Strong Buy
+498.6% avg upside
5 analysts
$35.00
902.93% Upside
 -16.2% ·
DE:MRK
Merck KGaA
 Aug 25, 2020 BUY Buy
+0.1% avg upside
33 analysts
$86.37
37.38% Downside
 +75.9% ·
FBRX
Forte Biosciences
 May 22, 2019 HOLD Buy
-35.4% avg upside
15 analysts
$5.00
93.44% Downside
 · ·
🔒 21 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Daina Graybosch — Frequently Asked Questions
How accurate are Daina Graybosch's stock ratings?
Based on the calls 13Foresight could measure, about 58% of Daina's ratings were profitable over a one-year hold, with an average return of +28.3% per rating, or +79.9% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Daina ranked on 13Foresight?
Daina Graybosch is currently ranked #323 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Daina cover?
Daina most recently has ratings on IPHA, REPL, GILD, CGEN, RCUS, BNTX, MRK, IPSC, SMMT, NBP, FATE, BOLT and 14 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.